Condition: Autoimmune Disease · Crohn Disease · Dermatomyositis · Sponsor: National Cancer Institute (NCI)
This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced), to other places in the body (metastatic) or cannot removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Chemotherapy drugs, such as platinum containing therapies and fluoropyrimidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab alone and in combination with other treatments, including ipilimumab, cabozantinib, platinum containing therapy, or fluoropyrimidine, may be safe, tolerable, and/or effective in treating patients with autoimmune disorders and advanced, metastatic, or unresectable cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Active Not Recruiting |
| Stanford Cancer Institute Palo Alto | Palo Alto, California, United States | Active Not Recruiting |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| Smilow Cancer Center/Yale-New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Emory University Hospital/Winship Cancer Institute | Atlanta, Georgia, United States | Active Not Recruiting |
| Northwestern University | Chicago, Illinois, United States | Active Not Recruiting |
| University of Chicago Comprehensive Cancer Center | Chicago, Illinois, United States | Active Not Recruiting |
| University of Kansas Clinical Research Center | Fairway, Kansas, United States | Recruiting |
| HaysMed | Hays, Kansas, United States | Recruiting |
| University of Kansas Cancer Center | Kansas City, Kansas, United States | Recruiting |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03816345